Supported by National Eye Institute R01 EY028284 (CAG, MAF), R01 EY026574 (MAF, CAG, LMZ), R01 EY 029058 (RNW), EY11008 (LMZ), EY19869 (LMZ), EY14267 (LMZ), EY027510 (LMZ), P30EY022589 (LMZ), EyeSight Foundation of Alabama (CAG, MAF), and Research to Prevent Blindness (CAG, MAF, RNW).
Disclosure: C.A. Girkin, Heidelberg Engineering, GmbH (F); M.A. Fazio, Heidelberg Engineering, GmbH (F), Equinox Ophthalmic (F), Vasoptic Medical, Inc. (F); C. Bowd, None; F.A. Medeiros, Alcon (C), Allergan (C, F), Ametek (C, F), Bausch & Lomb (F), Carl-Zeiss Meditec (C, F, R), Heidelberg Engineering (C, F), Sensimed (F), Topcon (F); R.N. Weinreb, Alcon (C), Aerie Pharmaceuticals (C, F), Allergan (C), Bausch & Lomb (C), Carl Zeiss Meditec (C, F), Centervue (F), Eyenovia (C), Genentech (F), Heidelberg Engineering (F), Implandata (C), Meditec-Zeiss (F), Optovue (F), Topcon (C, F); J.M. Liebmann, Alcon (C), Allergan (C), Bausch & Lomb (C, F), Carl Zeiss Meditec (C, F), Heidelberg Engineering (C, F), National Eye Institute (F), Optovue (F), Reichert (C, F), Topcon (F), Valeant Pharmaceuticals (C); J. Proudfoot, None; L.M. Zangwill, Carl Zeiss Meditec (F), Heidelberg Engineering (F, R), National Eye Institute (F), Optovue, Inc. (F), Topcon Medical System, Inc. (F); A. Belghith, None